Abstract
Objectives: This study investigates the effect of fosfomycin on the tumoricidal efficacy of cisplatinum. Study Design: Prospective study utilizing the FaDu squamous cell carcinoma cell line and a nude mouse tumor xenograft model. Methods: Tumor cell growth was assessed in vitro in the presence of cisplatinum and/or fosfomycin utilizing the MTT assay. An optimal cisplatinum dose and dosing schedule was established in a nude mouse tumor xenograft model of squamous cell carcinoma. Using this model, fosfomycin was tested at three dosages and tumor growth monitored over 4 weeks. Results: Mice treated with cisplatinum and fosfomycin had smaller tumors than those treated with cisplatinum alone (P < .01). Conclusions: This study is the first demonstration that fosfomycin does not inhibit the tumoricidal efficacy of cisplatinum in vivo. This suggests that fosfomycin may be useful in preventing cisplatinum-induced ototoxicity and nephrotoxicity in humans without altering the tumor response rate.
Original language | English (US) |
---|---|
Pages (from-to) | 1259-1262 |
Number of pages | 4 |
Journal | Laryngoscope |
Volume | 109 |
Issue number | 8 |
DOIs | |
State | Published - Aug 1999 |
Keywords
- Cisplatinum
- Fosfomycin
- Squamous cell carcinoma
ASJC Scopus subject areas
- Otorhinolaryngology